Data layers Raw facts Calculated Model prediction AI interpretation

Cross-Market Price Comparison

Other Listed Market Shanghai (SSE) — 君实生物
Other Market Stock Code688180
H-Share Offer PriceTo be extracted
Other Market PriceLoading...
Reference Exchange RateLoading...
H-Share Offer Price Premium/Discount vs Other MarketLoading...

Company Overview

Stock NameJunshi Bio
Stock Code01877
Company Full NameTo be extracted
IndustryHealthcare
Principal Activities創新驅動型生物製藥公司,致力於創新藥物的發現和開發,以及全球臨床研究及商業化。利用蛋白質工程核心平台技術,專注腫瘤免疫療法、自身免疫性疾病及代謝疾病治療,擁有多項在研生物藥品。
Listing Date2018-12-24
Listing Rules EraOld Rules
Listing Rules Chapter18A生物科技
Weighted Voting Rights (WVR)No
Registered Address (Mainland China)中國(上海)自由貿易試驗區蔡倫路781號602室
Business Address (Hong Kong)香港皇后大道東183號合和中心54樓
Place of IncorporationTo be extracted
Listing MethodTo be extracted
Listing BoardMain Board
Websitejunshipharma.com
Share Registrar卓佳证券登记有限公司 (Tricor Investor Services Limited)
Registrar Contact(852)2980 1333
A-Share/US Dual ListingNo

Offering Information

Offering Mechanism Mechanism A
Offer PriceHK$ 19.38 / shares
Offer Price RangeTo be extracted
Lot SizeTo be extracted
Entry ThresholdTo be extracted
Par ValueRMB 1.0 / shares
Offer Period2018-12-11 to 2018-12-14
Global Offering Shares158,910,000 shares
HK Public Offer Shares (Initial)15,892,000 shares (10.0%)
Public Offer Lots (Initial)To be extracted
International Placing Shares (Initial)143,018,000 shares (90.0%)
Offer Ratio~10.0%
Total Shares Post-IPO760,310,000 shares
Greenshoe (Over-allotment Option)Yes
Stabilizing Manager (Greenshoe)To be extracted
Cornerstone Share61.5%
Clawback TiersTo be extracted
Reallocation OptionYes
Total Global Offering SizeHK$ 3,079,675,800

Stock Connect Inclusion Analysis

HK Market Cap HK$ 5.03B
Analysis Result Already included in Stock Connect (both)

Valuation & Financials

Market Cap (at Offer Price)To be extracted
Pre-IPO Valuation (Last Round)Not disclosed
P/E Ratio不適用(公司處於虧損狀態)
Profit/Loss Status亏损人民幣321.1百萬元
Period-End Cash Balance人民幣266.3百萬元
Listing ExpensesTo be extracted
Listing Expenses / Funds RaisedTo be extracted
Total Pre-IPO InvestmentTo be extracted

Financial Data

Unit: '000 RMB
Income Statement
Item 201620172018-06
Revenue 3,7571,148
Cost of sales -986-446
Gross profit 2,771702
Other income and gains, net 16,40952,3422,635
Administrative expenses -42,760-73,752-49,792
Net finance costs -2,439
Share of associates and JVs 31-3
Profit before tax -131,249-320,744-272,977
Income tax expense -241-5870
Profit for the year -131,967-321,071-272,760
Profit attributable to owners -131,020-320,844-272,786
Balance Sheet
Item 201620172018-06
Cash and cash equivalents 111,387266,298391,919
Trade and bills receivables 514220
Inventories 7,08630,60346,887
Total equity 1,126,6151,119,3341,153,797
Equity attributable to owners 1,127,5621,120,5081,154,945
Interest-bearing borrowings 00229,687
Cash Flow Statement
Item 201620172018-06
Net cash from operating activities -185,207-347,076-263,626
Net cash from investing activities -717,176187,712-130,100
Net cash from financing activities 646,286319,634514,489
Net increase in cash -256,097160,270120,763
Depreciation of PP&E 842165631
Purchase of PP&E -199,789-263,721-189,714
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
First Day CloseHK$ 23.75
First Day OpenHK$ 23.5
First Day Change22.55%
First Day Volume18500500.0
First Day Turnover431273000.0
Use of Proceeds
1、約40%或1177.60百萬港元的所得款項凈額將用于研發及商業化核心產品JS001,為JS001的臨床試驗提供資金; 2、約16%或471.04百萬港元的所得款項凈額將用于研發其他在研藥品,為臨床試驗提供資金; 3、約9%或264.96百萬港元的所得款項凈額將用于興建臨港生產基地及吳江生產基地; 4、約25%或736.00百萬港元的所得款項凈額將用于投資及收購制藥行業的公司,特別是具有與本公司互補的強大研發及/或商業化能力的公司; 5、約10%或294.40百萬港元的所得款項凈額將用作營運資金及其他一般企業用途。

Underwriting Syndicate

Sole Sponsor (1)
中国国际金融香港证券有限公司 CE AEN894
Overall Coordinators (4)
中国国际金融香港证券有限公司 CE AEN894 Citigroup Global Markets Asia Limited CE AAA137 Credit Suisse (Hong Kong) Limited CE AAO017 Fosun International Securities Limited CE AAF432
Joint Bookrunners (6)
中国国际金融香港证券有限公司 CE AEN894 Citigroup Global Markets Asia Limited CE AAA137 Credit Suisse (Hong Kong) Limited CE AAO017 Fosun International Securities Limited CE AAF432 中信建投(国际)融资有限公司 CE BAU112 CAITONG INTERNATIONAL SECURITIES CO., LIMITED CE AZF063
Joint Lead Managers (6)
中国国际金融香港证券有限公司 CE AEN894 Citigroup Global Markets Asia Limited CE AAA137 Credit Suisse (Hong Kong) Limited CE AAO017 Fosun International Securities Limited CE AAF432 中信建投(国际)融资有限公司 CE BAU112 CAITONG INTERNATIONAL SECURITIES CO., LIMITED CE AZF063

Cornerstone Investors

#Investor NameInvestment AmountShares Subscribed% of Offer Shares% of Total SharesLock-up PeriodEst. Unlock Date
1 Highbury Investment Pte Ltd 352,522,200 HKD — 11.45% — 6 months 2019-06-24
2 Loyal Valley Capital Advantage Fund LP 720,722,820 HKD — 23.40% — 6 months 2019-06-24
3 Megastar Investment Management Limited 117,500,940 HKD — 3.82% — 6 months 2019-06-24
4 TR Capital III, L.P. 23,488,560 HKD — 0.76% — 6 months 2019-06-24
5 北京鼎联鑫科技发展有限公司 164,516,820 HKD — 5.34% — 6 months 2019-06-24
6 王树君 258,509,820 HKD — 8.39% — 6 months 2019-06-24
7 俞建午 258,509,820 HKD — 8.39% — 6 months 2019-06-24

Directors & Management

PositionChinese nameEnglish Name
Chairman熊俊—
Company Secretary陳英格、袁頴欣—
No director data available.

Major Shareholders

Major Shareholders & Holdings熊鳳祥(直接持股9.74%)、熊俊(直接持股8.37%)、上海檀英(持股9.78%)、蘇州瑞源(直接持股7.25%)為主要股東;一致行動人士合計持股約22.04%。
About this page

This page shows Junshi Bio (01877) prospectus details: offer price range, fundraise size, cornerstone investors, greenshoe, Pool A/B allocation and syndicate. For eligible IPOs it also provides a Stock Connect inclusion analysis, indicating the pathway and estimated timing for Southbound Connect admission; for A-share / US secondary listings, it additionally compares the other market's price, exchange rate and the H-share premium/discount. Data is parsed from the HKEX prospectus and related announcements. New to IPO subscription? See Hong Kong IPO Subscription 101.

Cibo — HK IPO Allotment Forecasts, Allottee Profiling & Stock Connect